PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
Scott Antonia,Augusto Villegas,D. Daniel,D. Vicente,S. Murakami,Rina Hui,T. Kurata,Alberto Chiappori,Ki Hyeong Lee,M. De Wit,Byoung Chul Cho,M. Bourhaba,X. Quantin,T. Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos Stelios Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,J. de Castro Carpeño,C. Faivre-Finn,M. Reck, J. Vansteenkiste,D. Spigel,C. Wadsworth,M. Taboada,Phillip A. Dennis,Mustafa Ozguroglu Journal of Thoracic Oncology（2018）
关键词
NSCLC,durvalumab,PACIFIC
AI 理解论文
溯源树
样例
